Rooming-in for Infants at Risk of Neonatal Abstinence Syndrome

Sarah McKnight; Helen Coo; Gregory Davies; Belinda Holmes; Adam Newman; Lynn Newton; Kimberly Dow

doi:10.1055/s-0035-1566295

American Journal of Perinatology, Table of Contents

Am J Perinatol 2016; 33(05): 495-501
DOI: 10.1055/s-0035-1566295

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Rooming-in for Infants at Risk of Neonatal Abstinence Syndrome

Authors

Sarah McKnight

¹Department of Pediatrics, Queen's University, Kingston, Ontario, Canada
Helen Coo

¹Department of Pediatrics, Queen's University, Kingston, Ontario, Canada
Gregory Davies

²Department of Obstetrics & Gynaecology, Queen's University, Kingston, Ontario, Canada
Belinda Holmes

³Pediatrics Program, Kingston General Hospital, Kingston, Ontario, Canada
Adam Newman

⁴Department of Family Medicine, Queen's University, Kingston, Ontario, Canada
Lynn Newton

³Pediatrics Program, Kingston General Hospital, Kingston, Ontario, Canada
Kimberly Dow

¹Department of Pediatrics, Queen's University, Kingston, Ontario, Canada

Abstract

Objective To examine the impact of a rooming-in program for infants at risk of neonatal abstinence syndrome (NAS) on the need for pharmacologic treatment and length of hospitalization.

Study Design Our hospital implemented a rooming-in program for newborns at risk of NAS in June 2013. Previously, standard care was to admit these infants to the neonatal intensive care unit. Charts were reviewed to abstract data on at-risk infants born in the 13-month periods prior and subsequent to implementation of rooming-in (n = 24 and n = 20, respectively) and the groups were compared with the outcomes of interest.

Result Rooming-in was associated with a reduced need for pharmacologic treatment and shorter length of stay.

Conclusion These findings add to an emerging body of evidence on the health care resource utilization benefits associated with rooming-in for infants at risk of NAS. Future studies should evaluate a broader range of outcomes for this model of care.

Keywords

opioids - neonatal abstinence syndrome - rooming-in - length of stay - treatment

Full Text

References

References
1 Hayes MJ, Brown MS. Epidemic of prescription opiate abuse and neonatal abstinence. JAMA 2012; 307 (18) 1974-1975
2 Abrahams R, Chase C, Desmoulin J , et al. The opioid dependent mother and newborn- an update. The 6th Annual Ivey Symposium. J Popul Ther Clin Pharmacol 2012; 19 (1) e73-e77
3 Dow K, Ordean A, Murphy-Oikonen J , et al; Neonatal Abstinence Syndrome Work Group. Neonatal abstinence syndrome clinical practice guidelines for Ontario. J Popul Ther Clin Pharmacol 2012; 19 (3) e488-e506
4 Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012; 307 (18) 1934-1940
5 Anisfeld E, Lipper E. Early contact, social support, and mother-infant bonding. Pediatrics 1983; 72 (1) 79-83
6 Kennell JH, Klaus MH. Bonding: recent observations that alter perinatal care. Pediatr Rev 1998; 19 (1) 4-12
7 Saiki T, Lee S, Hannam S, Greenough A. Neonatal abstinence syndrome—postnatal ward versus neonatal unit management. Eur J Pediatr 2010; 169 (1) 95-98
8 Abrahams RR, Kelly SA, Payne S, Thiessen PN, Mackintosh J, Janssen PA. Rooming-in compared with standard care for newborns of mothers using methadone or heroin. Can Fam Physician 2007; 53 (10) 1722-1730
9 Hünseler C, Brückle M, Roth B, Kribs A. Neonatal opiate withdrawal and rooming-in: a retrospective analysis of a single center experience. Klin Padiatr 2013; 225 (5) 247-251
10 Newman A, Dow K, Davies G , et al. Introduction and evaluation of rooming-in as standard care for infants of opioid-dependent mothers at a tertiary care hospital. Can Fam Physician . In press
11 Abrahams RR, MacKay-Dunn MH, Nevmerjitskaia V, MacRae GS, Payne SP, Hodgson ZG. An evaluation of rooming-in among substance-exposed newborns in British Columbia. J Obstet Gynaecol Can 2010; 32 (9) 866-871
12 Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract 2014; 9 (1) 19
13 Hudak ML, Tan RC ; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 2012; 129 (2) e540-e560
14 Kaltenbach K, Holbrook AM, Coyle MG , et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction 2012; 107 (Suppl. 01) 45-52
15 Jones HE, Heil SH, Tuten M , et al. Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes. Drug Alcohol Depend 2013; 131 (3) 271-277
16 Johnson K, Greenough A, Gerada C. Maternal drug use and length of neonatal unit stay. Addiction 2003; 98 (6) 785-789
17 Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG 2009; 116 (5) 665-671
18 Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006; 117 (6) e1163-e1169
19 Ordean A, Kahan M, Graves L, Abrahams R, Kim T. Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a Canadian multisite cohort study. J Obstet Gynaecol Can 2015; 37 (3) 252-257
20 Eccles M, Grimshaw J, Campbell M, Ramsay C. Research designs for studies evaluating the effectiveness of change and improvement strategies. Qual Saf Health Care 2003; 12 (1) 47-52
21 Fan E, Laupacis A, Pronovost PJ, Guyatt GH, Needham DM. How to use an article about quality improvement. JAMA 2010; 304 (20) 2279-2287
22 Jones HE, Heil SH, Baewert A , et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012; 107 (Suppl. 01) 5-27